Citius Pharmaceuticals Inc vs Jones Lang LaSalle Inc — how do they compare? Citius Pharmaceuticals Inc trades at $0.73 (market cap $20.01M), while Jones Lang LaSalle Inc trades at $365.99 (market cap $16.72B). The key difference: Jones Lang LaSalle Inc is far larger — about 835.6× Citius Pharmaceuticals Inc's market cap, and Jones Lang LaSalle Inc is trading nearer its 52-week high, Citius Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| CTXR | JLL | |
|---|---|---|
Market Cap | $20.01M | $16.72B |
Sector | Health | Real Estate |
52-Week High | $1.82 | $373.24 |
52-Week Low | $0.48 | $280.16 |
Enterprise Value | $16.23M | $19.48B |
Trailing returns across standard periods
Latest headlines on both assets
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →Jones Lang LaSalle provides a wide range of real estate-related services to owners, occupiers, and investors worldwide, including leasing, property and project management, and capital markets advisory. JLL's investment management arm, LaSalle Investment Management, manages over $70 billion for clients across diverse public and private real estate strategies.
Read more on JLL →